The use of modeling and simulation to guide clinical development of olmesartan medoxomil in pediatric subjects

Clinical Pharmacology and Therapeutics

Volumn 91, Issue 2, 2012, Pages 250-256

  Salazar, D E ^a   Song, S H ^a   Shi, J ^a,b   Rohatagi, S ^a,c   Heyrman, R ^a   Wada, D R ^d,e   Carrothers, T J ^d  

^a DAIICHI SANKYO INC   (United States)

^b ALLERGAN INC   (United States)

^c Piramal Enterprises Limited   (India)

^d PHARSIGHT CORPORATION   (United States)

^e Quantitative Solutions   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OLMESARTAN;

ANTIHYPERTENSIVE ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE REGULATION; BODY WEIGHT; CHILD; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG MEGADOSE; DRUG POTENCY; GROUPS BY AGE; HUMAN; LOW DRUG DOSE; PHARMACOLOGICAL PARAMETERS; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; PROBABILITY; RACE DIFFERENCE; RECOMMENDED DRUG DOSE; SIMULATION; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE;

ADOLESCENT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPERTENSION; IMIDAZOLES; INFANT; MODELS, STATISTICAL; TETRAZOLES;

EID: 84855974349     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.220     Document Type: Article

References (17)

1. Ogden, L.G., He, J., Lydick, E. & Whelton, P.K. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension 35, 539-543 (2000). (Pubitemid 30108145)
2. Turnbull, F.; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362, 1527-1535 (2003). (Pubitemid 37410190)
3. Benjamin, D.K. Jr et al. Pediatric antihypertensive trial failures: analysis of end points and dose range. Hypertension 51, 834-840 (2008). (Pubitemid 351654692)
4. Jadhav, P.R., Zhang, J. & Gobburu, J.V. Leveraging prior quantitative knowledge in guiding pediatric drug development: a case study. Pharm. Stat. 8, 216-224 (2009).
5. Neutel, J.M. Clinical studies of CS-866, the newest angiotensin II receptor antagonist. Am. J. Cardiol. 87, 37C-43C (2001). (Pubitemid 32385761)
6. Chrysant, S.G., Weber, M.A., Wang, A.C. & Hinman, D.J. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am. J. Hypertens. 17, 252-259 (2004). (Pubitemid 38293331)
7. Chrysant, S.G., Melino, M., Karki, S., Lee, J. & Heyrman, R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin. Ther. 30, 587-604 (2008). (Pubitemid 351680489)
8. Oparil, S., Melino, M., Lee, J., Fernandez, V. & Heyrman, R. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin. Ther. 32, 1252-1269 (2010).
9. Hazan, L., Hernédez Rodriguez, O.A., Bhorat, A.E., Miyazaki, K., Tao, B. & Heyrman, R.; Assessment of Efficacy and Safety of Olmesartan in Pediatric Hypertension Study Group. A double-blind, dose-response study of the efficacy and safety of olmesartan medoxomil in children and adolescents with hypertension. Hypertension 55, 1323-1330 (2010).
10. Yoshihara, K., Gao, Y., Shiga, H., Wada, D.R. & Hisaoka, M. Population pharmacokinetics of olmesartan following oral administration of its prodrug, olmesartan medoxomil: in healthy volunteers and hypertensive patients. Clin. Pharmacokinet. 44, 1329-1342 (2005). (Pubitemid 41832573)
11. Flynn, J.T. et al.; PATH-1 Investigators. A randomized, placebo-controlled trial of amlodipine in children with hypertension. J. Pediatr. 145, 353-359 (2004). (Pubitemid 39165684)
12. Sakarcan, A. et al. The pharmacokinetics of irbesartan in hypertensive children and adolescents. J. Clin. Pharmacol. 41, 742-749 (2001). (Pubitemid 32612437)
13. Shahinfar, S. et al. A double-blind, dose-response study of losartan in hypertensive children. Am. J. Hypertens. 18, 183-190 (2005). (Pubitemid 40332547)
14. US Food and Drug Administration. Summaries of medical and clinical pharmacology reviews of pediatric studies. 〈http://www.fda.gov./Drugs/ Development Approval Process/Development Resources/ucm 049872.htm.
15. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 114, 555-576 (2004).
16. US Department of Health and Human Services. National Center for Health Statistics. Third National Health and Nutrition Examination Survey, 1988-1994 (Centers for Disease Control and Prevention, Hyattsville, MD, 2001).
17. Rohatagi, S., Carrothers, T.J., Kshirsagar, S., Khariton, T., Lee, J. & Salazar, D. Evaluation of population pharmacokinetics and exposure-response relationship with coadministration of amlodipine besylate and olmesartan medoxomil. J. Clin. Pharmacol. 48, 823-836 (2008). (Pubitemid 351871961)